GlassScriptPhysician profile
Shamlan Sheikh
NPI 1487077194
$1,795.87
in general payments reported to CMS, 2019-2025
21 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.41 · 2024: $210 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,369 · Education: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,369.41 |
| Education | $339.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $283.90 | 2019-2025 | Repatha |
| Abbott Laboratories | $276.05 | 2025 | Ensite |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $226.60 | 2025 | Lifevest |
| Abiomed | $189.34 | 2025 | |
| Esperion Therapeutics, INC. | $152.40 | 2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.29 | 2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $121.84 | 2024 | Uptravi, Opsumit |
| Jazz Pharmaceuticals INC. | $95.63 | 2025 | |
| Argenx US, INC. | $40.90 | 2024 | Vyvgart Hytrulo |
| Pfizer INC. | $36.93 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.97 | 2025 | Entyvio |
| Alnylam Pharmaceuticals INC. | $26.77 | 2025 | Onpattro |
| Lantheus Medical Imaging, INC. | $26.25 | 2025 | |
| Inspire Medical Systems, INC. | $25.29 | 2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $22.19 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $22.18 | 2024 | |
| Scpharmaceuticals INC. | $22.06 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $20.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.95 | 2025 | |
| Boston Scientific Corporation | $17.09 | 2025 | Accolade Sr |
| Cala Health, INC. | $14.24 | 2025 | Cala Kiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shamlan Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.